Brensocatib 10 mg + Brensocatib 25 mg + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Cystic Fibrosis Bronchiectasis
Conditions
Non-Cystic Fibrosis Bronchiectasis
Trial Timeline
Dec 1, 2020 → Oct 28, 2024
NCT ID
NCT04594369About Brensocatib 10 mg + Brensocatib 25 mg + Placebo
Brensocatib 10 mg + Brensocatib 25 mg + Placebo is a phase 3 stage product being developed by Insmed for Non-Cystic Fibrosis Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04594369. Target conditions include Non-Cystic Fibrosis Bronchiectasis.
What happened to similar drugs?
0 of 2 similar drugs in Non-Cystic Fibrosis Bronchiectasis were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04594369 | Phase 3 | Completed |
| NCT03218917 | Phase 2 | Completed |
Competing Products
8 competing products in Non-Cystic Fibrosis Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 32 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 35 |
| CSL787 + Placebo | CSL | Phase 2 | 42 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 47 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 35 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 32 |
| Brensocatib | Insmed | Pre-clinical | 23 |
| AP-PA02 | Armata Pharmaceuticals | Phase 2 | 25 |